We found that cancer cells with a high basal level of AMPK activity (e.g., UMSCC1 cells) were resistant or minimally responsive to cetuximab-induced growth inhibition despite effective inhibition of cell signaling pathways downstream of EGFR. The gene discussed is EGFR; the disease is cancer.